Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytek BioSciences

3.55
-0.0050-0.14%
Volume:22.88K
Turnover:81.67K
Market Cap:449.01M
PE:-39.94
High:3.58
Open:3.55
Low:3.52
Close:3.55
Loading ...

Cytek Biosciences Is Maintained at Overweight by Piper Sandler

Dow Jones
·
04 Mar

Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)

TIPRANKS
·
04 Mar

Cytek Biosciences price target lowered to $8 from $8.25 at Piper Sandler

TIPRANKS
·
04 Mar

Cytek Biosciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
01 Mar

Cytek Biosciences Inc (CTKB) Q4 2024 Earnings Call Highlights: Strong International Growth and ...

GuruFocus.com
·
28 Feb

Cytek Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates

Zacks
·
28 Feb

Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M

TIPRANKS
·
28 Feb

Cytek Biosciences Q4 EPS $0.07 Beats $0.05 Estimate, Sales $57.48M Miss $59.38M Estimate

Benzinga
·
28 Feb

BRIEF-Cytek Biosciences Q4 Revenue USD 57.5 Million Vs. IBES Estimate USD 59.4 Million

Reuters
·
28 Feb

Cytek Biosciences Q4 Adjusted Gross Margin 59%

THOMSON REUTERS
·
28 Feb

Cytek Biosciences Q4 Adjusted Ebitda USD 12.532 Million

THOMSON REUTERS
·
28 Feb

Cytek Biosciences Q4 Revenue USD 57.5 Million VS. Ibes Estimate USD 59.4 Million

THOMSON REUTERS
·
28 Feb

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

GlobeNewswire
·
28 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Feb

Goldman Sachs Downgrades Cytek Biosciences to Sell From Buy, Adjusts Price Target to $4.50 From $7

MT Newswires Live
·
31 Jan

Cytek Biosciences (CTKB) was downgraded to a Sell Rating at Goldman Sachs

TIPRANKS
·
31 Jan

Cytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the company

Simply Wall St.
·
27 Jan

Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 24% drop adds to a year losses

Simply Wall St.
·
20 Jan

Cytek Biosciences Down Over 21%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk

Dow Jones
·
16 Jan